Pantoprazole Sodium
Product manufactured by Denton Pharma, Inc. Dba Northwind Pharmaceuticals
Indications and Purposes
| 1 Indications And Usage Pantoprazole Is A Proton Pump Inhibitor Indicated (ppi) For The Following: Short-Term Treatment Of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (gerd) ( 1.1 ) Maintenance Of Healing Of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ze) Syndrome ( 1.3 ) Pantoprazole Sodium Delayed-Release Tablets Are Indicated For: 1.1 Short-Term Treatment Of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (gerd) Pantoprazole Sodium Delayed-Release Tablets Are Indicated In Adults And Pediatric Patients Five Years Of Age And Older For The Short-Term Treatment (up To 8 Weeks) In The Healing And Symptomatic Relief Of Erosive Esophagitis (ee). For Those Adult Patients Who Have Not Healed After 8 Weeks Of Treatment, An Additional 8-Week Course Of Pantoprazole Sodium Delayed-Release Tablets May Be Considered. Safety Of Treatment Beyond 8 Weeks In Pediatric Patients Has Not Been Established. 1.2 Maintenance Of Healing Of Erosive Esophagitis Pantoprazole Sodium Delayed-Release Tablets Are Indicated For Maintenance Of Healing Of Ee And Reduction In Relapse Rates Of Daytime And Nighttime Heartburn Symptoms In Adult Patients With Gerd. Controlled Studies Did Not Extend Beyond 12 Months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison (ze) Syndrome Pantoprazole Sodium Delayed-Release Tablets Are Indicated For The Long-Term Treatment Of Pathological Hypersecretory Conditions, Including Zollinger-Ellison (ze) Syndrome. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Pantoprazole Sodium |
|
ZINC4099200 |